Express Scripts Holding Co., a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. to cut the $84,000 price of its new hepatitis C pill Sovaldi.
California’s limit of $250,000 on medical malpractice damages for pain and suffering, which became a model for other states almost 40 years ago, could be increased under a voter initiative to be submitted today.
Greece wants to triple the share of generic drugs prescribed by the end of next year, closing the gap to targets set by international creditors under the terms of the country’s bailout, Health Minister Adonis Georgiades said.
The Food and Drug Administration banned imports from a plant operated by Mumbai-based Sun Pharmaceutical Industries Ltd. amid widening scrutiny of Indian drugmakers that feed the $93 billion U.S. generics market.
The number of Americans taking attention deficit hyperactivity disorder medicines rose 36 percent in 2012 from 2008, led by an surge among women, according to drug-benefits manager Express Scripts Holding Co.
Purdue Pharma LP plans to apply for regulatory approval of a tamper-resistant competitor to Zogenix Inc.’s powerful pain pill, a move that could get its rival’s drug pulled from the market by U.S. regulators.
Nestle SA paid $3.6 billion yesterday to take full control of Galderma, the dermatology business that revives skin. Nestle Chief Executive Officer Paul Bulcke will need to do the same at the unit to spur growth.
Teva Pharmaceutical Industries Ltd. is using records from its 24-hour support hotline in the U.S. to persuade thousands of multiple sclerosis patients to switch from its biggest-selling drug, Copaxone, to a new version that has patent protection until 2030.